Achillion Pharmaceuticals (ACHN) has risen sharply, recording gains of 3.14% in the past 4 weeks. However, the stock has corrected -3.5% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 3.36% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
Company shares have received an average consensus rating of Hold for the current week The stock has recorded a twenty day Moving Average of 2.87% and the fifty day Moving Average is 0.76%. Achillion Pharmaceuticals, Inc. has dropped 6.15% during the last three month period . Year-to-Date the stock performance stands at -20.85%.
Achillion Pharmaceuticals (ACHN) : 8 Wall Street analysts covering Achillion Pharmaceuticals (ACHN) believe that the average level the stock could reach for the short term is $9.38. The maximum price target given is $17 and the minimum target for short term is around $4, hence the standard deviation is calculated at $4.03.
Achillion Pharmaceuticals (NASDAQ:ACHN): On Fridays trading session , Opening price of the stock was $8.59 with an intraday high of $8.73. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $8.41. However, the stock managed to close at $8.54, a loss of 0.70% for the day. On the previous day, the stock had closed at $8.6. The total traded volume of the day was 1,050,599 shares.
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.